WD
Therapeutic Areas
Invivyd Pipeline
| Drug | Indication | Phase |
|---|---|---|
| VYD222 (Invymab) | Prevention of COVID-19 | Phase 3 |
| Next-Generation COVID-19 mAb | COVID-19 | Preclinical/Discovery |
| Influenza mAb Programs | Influenza | Discovery/Preclinical |
Leadership Team at Invivyd
MM
Michael Mina
Chief Medical Officer
RA
Robert Allen
Chief Scientific Officer
JA
Jill Andersen
Chief Legal Officer & Corporate Secretary
RG
Rachael Gerlach
Senior Vice President of Regulatory Affairs
JG
Julie Green
Chief Human Resources Officer
TL
Timothy Lee
Chief Commercial Officer